Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you live in Guildford and have been looking into weight loss injections, here is the direct answer: Mounjaro (tirzepatide) and Wegovy (semaglutide) are prescription-only medicines licensed in the UK for weight management, available through regulated online pharmacies without a GP referral or a wait for a local clinic. A clinician reviews your case and, if suitable, treatment is dispatched the same day. These are serious medical treatments, not lifestyle supplements, and a prescriber must assess your health before any medicine is issued.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you've searched for somewhere local, found a handful of results, and wondered whether you have to book a face-to-face appointment, travel to a clinic and wait weeks for a slot. For many people in Guildford, that used to be the only realistic route. It is not any more.
Mounjaro and Wegovy are subcutaneous injections you give yourself once a week. The pen arrives ready to use. That means the physical location of a pharmacy is largely irrelevant, what matters is that the pharmacy is GPhC-registered, that a qualified prescriber reviews your consultation properly, and that the medicine travels to you through the licensed UK supply chain. You can check any online pharmacy on the GPhC pharmacy register before you hand over any personal details.
At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day it is submitted, not processed by software, not queued for a bot. If you order before 12pm Monday to Friday and your consultation is approved, the pen leaves our pharmacy that afternoon via DPD tracked delivery, arriving the next working day in plain packaging. For most people in Guildford, that means next-day delivery at home or to a work address. The logistics are simple. The clinical part is what takes care.
A question our prescribers hear most weeks is some version of: "Is Mounjaro stronger than Wegovy, or should I just go with whichever is cheaper?" It is a fair question, and the answer is more nuanced than any headline figure suggests.
Mounjaro is tirzepatide, made by Eli Lilly. It is the only dual GIP and GLP-1 receptor agonist licensed for weight management in the UK. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants on the highest dose lost around 20 to 21 percent of their body weight on average over 72 weeks. Wegovy is semaglutide, made by Novo Nordisk, and works on the GLP-1 pathway alone. The STEP 1 trial reported around 15 percent average weight loss at the standard 2.4mg maintenance dose over 68 weeks. A newer 7.2mg dose of Wegovy was approved by the MHRA in early 2026 and showed results approaching those of tirzepatide in trials. Head-to-head, the SURMOUNT-5 trial found tirzepatide produced greater average weight loss than semaglutide 2.4mg directly compared.
Neither is categorically "right" for everyone. The prescriber's job (and the point of a proper consultation) is to look at your health history, any medicines you already take, and your BMI before making a recommendation. You can read a fuller comparison of the two on our guide to the main licensed weight loss injections.
Private eligibility broadly follows the licensed indications: adults aged 18 or over with a BMI of 30 or above, or a BMI of 27 or above plus at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI figure alone does not guarantee a prescription, the prescriber assesses the full picture.
On the NHS, tirzepatide (Mounjaro) is being rolled out in phases through GP practices from 2025 onwards under NICE guidance TA1026, but criteria are strict and phased by comorbidity count. Many people in Guildford will not meet the current NHS thresholds, or will face a significant wait even if they do. If you are based further north and exploring your options, you can find detail specific to your area in our guide to weight loss injections in Bradford. Private treatment through a regulated pharmacy is an alternative for people who are clinically suitable but do not want to wait.
Cost is a common concern, and it is worth being honest about it. Mounjaro's UK list price rose significantly from September 2025, and private prices typically range from around £149 to £375 per month depending on the dose and provider. If you want to understand what that figure includes (and what some providers leave out) our breakdown of injection costs covers it clearly. There are also practical options for making treatment more manageable, explored in our guide on affording weight loss injections. At nume, one price covers the consultation, prescription, medicine and next-day delivery, no subscription, no hidden extras.
Side effects are common, particularly in the first few weeks or after a dose increase. Nausea tops the list for most people, followed by looser stools or constipation, reflux and tiredness. These are typically mild to moderate and settle as your system adjusts, eating smaller portions and staying well hydrated helps. The NHS tirzepatide page lists the full side effect profile alongside advice on when to contact a doctor.
There are symptoms that warrant urgent medical attention. Severe, persistent stomach pain that spreads to the back (with or without vomiting) can indicate pancreatitis, which the MHRA flagged in a Drug Safety Update in January 2026 as an infrequent but serious risk with GLP-1 medicines. Do not wait to see if it passes; call 111 or go to A&E. Signs of a serious allergic reaction (swelling, difficulty breathing, rapid heart rate) also need emergency care.
Women using oral contraceptives should be aware that tirzepatide can reduce pill absorption during the first four weeks of treatment and for four weeks after any dose increase, a barrier method is recommended during those windows. If you are pregnant, breastfeeding or trying to conceive, these medicines are not recommended. Under-18s are not licensed to use them. For questions specific to your situation, our overview of how these injections work in practice covers the main practical points, and our team is available seven days a week via our contact page.
Speak to our prescribers if you are ready to find out whether treatment is right for you, the free consultation takes a few minutes and is reviewed the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.